VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
PETS
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
PETSPetMed Express, Inc.
$1.22$26M
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
PETS logo

PetMed Express, Inc.

PETS
NASDAQ · Specialty Retail Stores
$1.22
At close - Nov 6, 4:00 PM EST - USD
Market Cap$26M
P/E-0.9x
52W High$4.10
Volume29.54K
OverviewTerminalAnalysisFinancialsValuationEarningsBreakoutsOwnership
VCP Research Verdict2026Q4

Persistent Revenue Contraction Threatens Operational Solvency

PetMed Express faces a critical inflection point as its legacy transactional model struggles to compete against integrated e-commerce platforms, resulting in a 21.13% year-over-year revenue decline.

GrowthContracting
ProfitabilityNegative
ValuationReview
TechnicalsWeak
Explore valuation models
MARKET ACTION

PETS price & volume

Price trend, volume and key moving averages

Launch Terminal
Loading chart...
Decision Checklist4 Core Signals

What matters now

The signals most likely to change the investment case.

01

Earnings momentum

2/12 Beats

EPS beat 2 of last 12 quarters

02

Valuation risk

-103% Peers

P/E is 103% below peer median

03

Market leadership

RS 16 · Lag

Laggard (Underperforming 84% of market)

04

Weak Trend

Below 200DMA

Price < 200DMA

Next CatalystConfirmed earnings · Nov 10

Market performance

Price History →

Trailing total returns as of 11/7/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).

YTD Return
PETS-63.03%
S&P 500 (^GSPC)+7.63%
1-Year Return
PETS-50.20%
S&P 500 (^GSPC)+9.69%
3-Year Return
PETS-82.82%
S&P 500 (^GSPC)+67.48%
5-Year Return
PETS-89.42%
S&P 500 (^GSPC)+56.25%
02

Test the fundamentals

Check whether operating performance supports the current valuation.

VALUATION & INTRINSIC VALUE

Valuation Scenarios

Valuation Analysis
Trailing P/E5Y Low
-0.9x
Forward P/E
N/A
EV/EBITDA
N/A
FCF YieldCash Flow
N/A

Valuation vs 5-Year History

Multiple Range
Metric
Current
5Y Median
Historical Range
Percentile
P/E
-0.9x
65.0x
0th· Low
EV/EBITDA
N/A
22.5x
N/A
Price/FCF
N/A
31.4x
N/A
Current Multiple
5Y Median (50th %ile)

Intrinsic Value Scenarios

DCF Projection
No DCF Model AvailableIntrinsic value modeling is not supported for this equity.

Growth & profitability

Annual revenue & EPS trend
Revenue FY26
$179M-21.1% YoY
Net income FY26
-$57M-813.5% YoY
Free cash flow FY26
-$33M-8256.7% YoY
Operating margin FY26
-17.5%-16.9 pts YoY
ROIC (FY26)-119.4%
Avg ROIC 5Y-9.1%
ROE (TTM)-91.7%
Piotroski Score3 / 9
Financial Statements →
03

Monitor what changed

Recent results and news deserve attention only when they alter the forward view.

OPERATING RESULTS

Recent Earnings

Earnings History
EPS Beat Rate2/12 (17%)
Revenue Beat Rate3/12 (25%)
QuarterEPS (Act vs Est)Revenue (Act vs Est)
Q3 2026Latest
Aug 13, 2026
-$0.28-333.3%
vs $0.12
$41M-42.2%
vs $71M
Q3 2026
Jun 2, 2026
-$0.19-5.6%
vs -$0.18
$43M-17.7%
vs $52M
Q1 2026
Feb 5, 2026
-$0.50-733.3%
vs -$0.06
$41M-24.8%
vs $54M
Q4 2025
Dec 19, 2025
-$0.34-1600.0%
vs -$0.02
$44M-36.0%
vs $69M
Historical baseline: 12 quarters analyzedGAAP / Adjusted
MARKET COVERAGE

Latest News

4 Stories
GlobeNewsWire·Oct 27, 2026
PetMed Express, Inc. to Report Second Quarter Fiscal Year 2027 Financial Results on Tuesday, November 10, 2026

DELRAY BEACH, Fla., Oct. 27, 2026 (GLOBE NEWSWIRE) -- PetMed Express, Inc., dba PetMeds and parent company of PetCareRx, (Nasdaq: PETS) today announced it will report financial results for the second quarter fiscal year ended September 30, 2026, on Tuesday, November 10, 2026 after market close. The Company will host a conference call and webcast to review these results at 4:30pm Eastern Time on the same day.

GlobeNewsWire·Oct 2, 2026
PetMeds Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

DELRAY BEACH, Fla., Oct. 02, 2026 (GLOBE NEWSWIRE) -- PetMed Express, Inc., dba PetMeds and parent company of PetCareRx (Nasdaq: PETS), today announced that PetMeds recently granted equity awards previously approved by its Board of Directors to two newly hired executives as a material inducement to employment.

GlobeNewsWire·Sep 21, 2026
PetMeds Enhances Board of Directors with Appointment of Tamar Elkeles as New Independent Director

Dr. Elkeles Brings Deep Experience and Proven Track Record in Shaping Human Capital Strategy to Support Strategic Growth and Operational Execution Dr. Elkeles Brings Deep Experience and Proven Track Record in Shaping Human Capital Strategy to Support Strategic Growth and Operational Execution

GlobeNewsWire·Sep 17, 2026
PetMeds Appoints Jeff Willard as CEO & President and Announces Board Leadership Transition

Justin Mennen to Succeed Leslie C.G. Campbell as Chair of the Board Following Her Retirement Justin Mennen to Succeed Leslie C.G. Campbell as Chair of the Board Following Her Retirement

Filtered for PetMed Express, Inc.More Headlines
04

Compare before deciding

Benchmark PETS against direct peers instead of judging its metrics in isolation.

Peers Comparison

Key metrics vs top competitors for PetMed Express, Inc. (PETS)

Full Screener →
CompanyPriceMarket CapP/E RatioRev Growth (1Y)Net MarginROEDiv Yield
PETS logoPETSPetMed Express, Inc.Current
$1.22$26.07M-0.90-21.13%-17.34%-91.67%0.08%
CHWY logoCHWYChewy, Inc.
$22.56$9.34B33.806.24%2.09%62.13%—
WOOF logoWOOFPetco Health and Wellness Company, Inc.
$2.96$845.27M28.41-2.53%0.51%2.58%—
FRPT logoFRPTFreshpet, Inc.
$64.39$3.16B26.8013.01%10.9%10.65%—
HIMS logoHIMSHims & Hers Health, Inc.
$26.00$5.8B-42.4259%-5.51%-30.03%—
TDOC logoTDOCTeladoc Health, Inc.
$8.77$1.58B-10.30-1.54%-6.27%-11.63%—

Compare PETS vs Peers

PetMed Express, Inc. (PETS) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs CHWY

Most directly comparable listed peer for PETS.

Scale Benchmark

vs AMZN

Larger-name benchmark to compare PETS against a more recognizable public peer.

Peer Set

Compare Top 5

vs CHWY, WOOF, FRPT, HIMS

05

Keep researching

Verify the primary filings, follow material updates, and answer the remaining questions.

PETS SEC Filings & Documents

PetMed Express, Inc. (PETS) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

6
Material company update

Aug 13, 2026·SEC

Material company update

Aug 12, 2026·SEC

Material company update

Jul 23, 2026·SEC

10-K Annual Reports

3
FY 2026

Jun 2, 2026·SEC

FY 2025

Oct 14, 2025·SEC

FY 2024

Jun 14, 2024·SEC

10-Q Quarterly Reports

6
FY 2026

Aug 13, 2026·SEC

FY 2026

Feb 5, 2026·SEC

FY 2025

Dec 19, 2025·SEC

Get notified when PETS posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

Free. Unsubscribe any time.

PETS Frequently Asked Questions

PetMed Express, Inc. (PETS) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials
What is PetMed Express, Inc.'s revenue?

PetMed Express, Inc. (PETS) reported $168.9M in revenue over the trailing twelve months. Revenue was $179.0M in fiscal year 2026. That is 1120% more than the $14.7M of fiscal year 2000.

How fast is PetMed Express, Inc. growing?

PetMed Express, Inc. (PETS) revenue fell by 19.7% over the trailing twelve months, compared with the twelve months before.

Is PETS profitable?

No. PetMed Express, Inc. (PETS) reported a net loss of $29.3M over the trailing twelve months.

Dividend & Returns
Does PETS pay dividends?

PetMed Express, Inc. (PETS) does not currently pay a meaningful dividend.

What is PETS's return on equity?

PetMed Express, Inc. (PETS) had a return on equity (ROE) of -91.7% over the trailing twelve months. A negative ROE means the company lost money over the period.

What is PetMed Express, Inc.'s free cash flow?

PetMed Express, Inc. (PETS) had negative free cash flow of $27.8M over the trailing twelve months.

What if you invested $1,000 in PETS back in 2000?

Total return calculator · dividends reinvested · 26+ years of data

See returns →